Novavax On Wild After-Hours Ride After Reporting COVID-19 Vaccine Data

8/5/20

By Douglas W. House, SA

At one point after hours, Novavax (NASDAQ:NVAX) was down ~30% after STAT News reported that eight participants in a Phase 1 clinical trial evaluating COVID-19 vaccine candidate NVX-CoV2373 had to be hospitalized, a point later found to be erroneous. NVAX apparently contacted STAT to say that no subjects required hospitalization.

The stock is now down only 3% on turnover of 4.7M shares according to Nasdaq.

READ FULL ARTICLE HERE

Recent Deals

Interested in advertising your deals? Contact Edwin Warfield.